DOI QR코드

DOI QR Code

A disappearing vertical infection: will hepatitis B be a forgotten disease in children?

  • Choe, Byung-Ho (Department of Pediatrics, Kyungpook National University School of Medicine)
  • 투고 : 2014.04.10
  • 심사 : 2014.04.18
  • 발행 : 2014.05.01

초록

키워드

참고문헌

  1. Choe BH. The epidemiology and present status of chronic hepatitis B in Korean children. Korean J Pediatr 2008;51:696-703. https://doi.org/10.3345/kjp.2008.51.7.696
  2. The Korean Centers for Disease Control and Prevention. 2012 Disease Control White Paper. Cheongwon: The Korean Centers for Disease Control and Prevention, 2012.
  3. Park SH. Trends in the seroprevalence of hepatitis B surface antigen in the South Korean population. Int J Infect Dis 2012;16:e669-e672. https://doi.org/10.1016/j.ijid.2012.05.1019
  4. Kim JH, Kim JS, Lee JJ, et al. Survey of perinatal hepatitis B virus transmission after Korean National Prevention Program in a tertiary hospital. Korean J Intern Med 2014;29:307-314. https://doi.org/10.3904/kjim.2014.29.3.307
  5. Pande C, Sarin SK, Patra S, et al. Hepatitis B vaccination with or without hepatitis B immunoglobulin at birth to babies born of HBsAg-positive mothers prevents overt HBV transmission but may not prevent occult HBV infection in babies: a randomized controlled trial. J Viral Hepat 2013;20:801-810.
  6. Lin HH, Lee TY, Chen DS, et al. Transplacental leakage of HBeAg-positive maternal blood as the most likely route in causing intrauterine infection with hepatitis B virus. J Pediatr 1987;111(6 Pt 1):877-881. https://doi.org/10.1016/S0022-3476(87)80210-X
  7. Ohto H, Lin HH, Kawana T, Etoh T, Tohyama H. Intrauterine transmission of hepatitis B virus is closely related to placental leakage. J Med Virol 1987;21:1-6. https://doi.org/10.1002/jmv.1890210102
  8. Kwiek JJ, Arney LA, Harawa V, et al. Maternal-fetal DNA admixture is associated with intrapartum mother-tochild transmission of HIV-1 in Blantyre, Malawi. J Infect Dis 2008;197:1378-1381. https://doi.org/10.1086/587646
  9. Yue YF, Jiang H, Shi L, et al. Study on the mechanism of intrauterine infection of hepatitis B virus. Zhonghua Fu Chan Ke Za Zhi 2004;39:224-226.
  10. Bhat P, Anderson DA. Hepatitis B virus translocates across a trophoblastic barrier. J Virol 2007;81:7200-7207. https://doi.org/10.1128/JVI.02371-06
  11. Xu DZ, Yan YP, Choi BC, et al. Risk factors and mechanism of transplacental transmission of hepatitis B virus: a case-control study. J Med Virol 2002;67:20-26. https://doi.org/10.1002/jmv.2187
  12. Bai H, Zhang L, Ma L, Dou XG, Feng GH, Zhao GZ. Relationship of hepatitis B virus infection of placental barrier and hepatitis B virus intra-uterine transmission mechanism. World J Gastroenterol 2007;13:3625-3630. https://doi.org/10.3748/wjg.v13.i26.3625
  13. Choe BH. Hepatitis B vaccine: prevention of perinatal infection and management of nonresponder. Korean J Pediatr Gastroenterol Nutr 2007;10(Suppl 1):91-100.
  14. Song YM, Sung J, Yang S, Choe YH, Chang YS, Park WS. Factors associated with immunoprophylaxis failure against vertical transmission of hepatitis B virus. Eur J Pediatr 2007;166:813-818. https://doi.org/10.1007/s00431-006-0327-5
  15. Wiseman E, Fraser MA, Holden S, et al. Perinatal transmission of hepatitis B virus: an Australian experience. Med J Aust 2009;190:489-492.
  16. Zou H, Chen Y, Duan Z, Zhang H, Pan C. Virologic factors associated with failure to passive-active immunoprophylaxis in infants born to HBsAg-positive mothers. J Viral Hepat 2012;19:e18-e25. https://doi.org/10.1111/j.1365-2893.2011.01492.x
  17. Kazim SN, Wakil SM, Khan LA, Hasnain SE, Sarin SK. Vertical transmission of hepatitis B virus despite maternal lamivudine therapy. Lancet 2002;359:1488-1489. https://doi.org/10.1016/S0140-6736(02)08425-8
  18. Xu WM, Cui YT, Wang L, et al. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. J Viral Hepat 2009;16:94-103. https://doi.org/10.1111/j.1365-2893.2008.01056.x
  19. Han GR, Cao MK, Zhao W, et al. A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. J Hepatol 2011;55:1215-1221. https://doi.org/10.1016/j.jhep.2011.02.032
  20. Celen MK, Mert D, Ay M, et al. Efficacy and safety of tenofovir disoproxil fumarate in pregnancy for the prevention of vertical transmission of HBV infection. World J Gastroenterol 2013;19:9377-9382. https://doi.org/10.3748/wjg.v19.i48.9377
  21. Yogeswaran K, Fung SK. Chronic hepatitis B in pregnancy: unique challenges and opportunities. Korean J Hepatol 2011;17:1-8. https://doi.org/10.3350/kjhep.2011.17.1.1
  22. Jiang HX, Han GR, Wang CM, Ji Y. Maternal-fetal outcomes of lamivudine treatment administered during late pregnancy to highly viremic mothers with HBeAg+ chronic hepatitis B. Zhonghua Gan Zang Bing Za Zhi 2012;20:888-891.
  23. ter Borg MJ, Leemans WF, de Man RA, Janssen HL. Exacerbation of chronic hepatitis B infection after delivery. J Viral Hepat 2008;15:37-41.
  24. Lee SD, Lo KJ, Tsai YT, et al. Role of caesarean section in prevention of mother-infant transmission of hepatitis B virus. Lancet 1988;2:833-834.
  25. Wang J, Zhu Q, Zhang X. Effect of delivery mode on maternal-infant transmission of hepatitis B virus by immunoprophylaxis. Chin Med J (Engl) 2002;115:1510-1512.
  26. Yin Y, Wu L, Zhang J, Zhou J, Zhang P, Hou H. Identification of risk factors associated with immunoprophylaxis failure to prevent the vertical transmission of hepatitis B virus. J Infect 2013;66:447-452. https://doi.org/10.1016/j.jinf.2012.12.008
  27. Pan CQ, Zou HB, Chen Y, et al. Cesarean section reduces perinatal transmission of hepatitis B virus infection from hepatitis B surface antigen-positive women to their infants. Clin Gastroenterol Hepatol 2013;11:1349-1355. https://doi.org/10.1016/j.cgh.2013.04.026
  28. Lin HH, Hsu HY, Chang MH, Chen PJ, Chen DS. Hepatitis B virus in the colostra of HBeAg-positive carrier mothers. J Pediatr Gastroenterol Nutr 1993;17:207-210. https://doi.org/10.1097/00005176-199308000-00014
  29. Hill JB, Sheffield JS, Kim MJ, Alexander JM, Sercely B, Wendel GD. Risk of hepatitis B transmission in breastfed infants of chronic hepatitis B carriers. Obstet Gynecol 2002;99:1049-1052. https://doi.org/10.1016/S0029-7844(02)02000-8
  30. Wang JS, Zhu QR, Wang XH. Breastfeeding does not pose any additional risk of immunoprophylaxis failure on infants of HBV carrier mothers. Int J Clin Pract 2003;57:100-102.
  31. Chen X, Chen J, Wen J, et al. Breastfeeding is not a risk factor for mother-to-child transmission of hepatitis B virus. PLoS One 2013;8:e55303. https://doi.org/10.1371/journal.pone.0055303
  32. Hong SJ, Park HJ, Chu MA, Choi BS, Choe BH. The rate of conversion from immune-tolerant phase to early immune-clearance phase in children with chronic hepatitis B virus infection. Pediatr Gastroenterol Hepatol Nutr 2014;17:41-46. https://doi.org/10.5223/pghn.2014.17.1.41
  33. Choe HJ, Choe BH. What physicians should know about the management of chronic hepatitis B in children: east side story. World J Gastroenterol 2014;20:3582-3589. https://doi.org/10.3748/wjg.v20.i13.3582
  34. Choe BH, Lee JH, Jang YC, et al. Long-term therapeutic efficacy of lamivudine compared with interferon-alpha in children with chronic hepatitis B: the younger the better. J Pediatr Gastroenterol Nutr 2007;44:92-98. https://doi.org/10.1097/01.mpg.0000243439.47334.4e
  35. Chu M, Cho SM, Choe BH, Cho MH, Kwon S, Lee WK. Virologic responses to add-on adefovir dipivoxil treatment versus entecavir monotherapy in children with lamivudine-resistant chronic hepatitis B. J Pediatr Gastroenterol Nutr 2012;55:648-652. https://doi.org/10.1097/MPG.0b013e318262a737
  36. Hong SJ, Kim YH, Choe BH, Park HJ, Tak WY, Kweon YO. Current role of Lamivudine regarding therapeutic response and resistance in children with chronic hepatitis B. Pediatr Gastroenterol Hepatol Nutr 2013;16:80-88. https://doi.org/10.5223/pghn.2013.16.2.80